The Future of Memory Disorders
This article was originally published in Start Up
Executive Summary
The market for products that boost memory and cognition is vast, and underserved. But until clinicians and companies define cognitive diseases and develop clinical models for them, start-ups developing memory drugs face an uncertain future. Included in this feature are profiles of Accera Inc., GBtherapeutics Ltd., Saegis Pharmaceuticals Inc. and Sention Inc.
You may also be interested in...
Sention Inc.
Sention Inc. is developing discovery tools, including a proprietary whole-animal assay system, that measure the genes and proteins involved in memory consolidation. It is using that platform to identify known drugs developed for other uses, and therefore with established safety profiles, which can regulate memory consolidation.
Saegis Pharmaceuticals Inc.
Saegis Pharmaceuticals Inc. hopes to be the first to market with therapies for mild cognitive impairment and age-related cognitive decline. Through a combination of in-licensing and internal drug development, it also plans to attack cognitive impairment related to stroke, brain trauma, and other neurological disorders.
Accera Inc.
Accera Inc. has a radically different theory about what causes Alzheimer's Disease. It ties the disease, and possibly its precursor mild cognitive impairment, to a decline in cerebral energy metabolism. The company's lead compounds are designed to address that shortfall.